A Phase I Clinical Study of GS3-007a Dry Suspensions in Healthy Chinese Adults: Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Dose, Dose-Escalation, and Food Effect Study
Latest Information Update: 28 Mar 2026
At a glance
- Drugs GS3-007 (Primary)
- Indications Somatotropin deficiency
- Focus Adverse reactions
- Sponsors GeneScience Pharmaceuticals
Most Recent Events
- 28 Mar 2026 New trial record